314 Phase 1 study of abemaciclib, a CDK 4 and 6 inhibitor, as a single agent for Japanese patients with advanced cancer. (September 2015) - Kondo, S.; Yamamoto, N.; Tamura, K.; Tanabe, Y.; Iwasa, S.; Shimomura, A.; Shibasaki, Y.; Ogasawara, K.; Turner-Jones, K.; Mori, J.; Asou, H.; Michael Chan, E.; et al.